Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | ESRRA | P11474 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | F10 | P00742 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640676 | 0.86 | F10 (0.40) | GAAESR1ESR2ESRRAKDM4E | |
| SCHEMBL3842545 | 0.85 | LMNA (0.38) | GAAESRRAKDM4ELMNAALDH1A1 | |
| SCHEMBL3834826 | 0.83 | F10 (0.34) | GAAF10 | |
| SCHEMBL3837759 | 0.75 | TP53 (0.47) | GAAKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL12727579 | 0.73 | GAA (0.42) | GAAKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3835105 | 0.72 | ROCK2 (0.36) | F10 | |
| SCHEMBL1639644 | 0.72 | LMNA (0.39) | GAALMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3839792 | 0.72 | EGFR (0.34) | GAAKDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL3834640 | 0.72 | MIF (0.33) | — | |
| SCHEMBL3836616 | 0.72 | MEN1 (0.34) | SMN1; SMN2MEN1KMT2AMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094272-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2009-09-02 | — | — | EP | claimed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| EP-2094272-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |